SUBSCRIBE
SUBSCRIBE
News   Policy

Regeneron Pharmaceuticals, Inc. Says FDA Extends Priority Review of CAPS Treatment

November 2, 2007 | 
1 min read
Nov 1 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O: Quote, Profile, Research) said U.S. regulators have extended the date for taking action on a priority review of the company's treatment for a rare chronic inflammatory disease known as CAPS.
Regulatory
Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie
Racing Cars at the finish line
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Pictured: Front view of the CDC museum in Georgia
CDC
RFK Jr. Appoints 2 New Advisors to CDC Vaccine Panel Ahead of March Meeting
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: BMS, GSK, Aldeyra and More
March 2, 2026
 · 
4 min read
 · 
Tristan Manalac